Cleveland BioLabs Receives First U.S. Patent For Radiation Protection Drug CBLB502

Main Category: Radiology / Nuclear Medicine
Article Date: 07 Jan 2010 - 15:00 PDT

email to a friend   printer friendly   opinions  

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that the U.S. Patent and Trademark Office has issued US Patent No. 7,638,485 titled "Modulating Apoptosis" covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO), and two additional nations.

Cleveland BioLabs has also filed two additional new patent applications related to Protectan technology in the U.S. around various aspects and properties for CBLB502 and related Protectan compounds, including new methods of use of flagellin derivatives and screening for new compounds with similar properties.

Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, noted, "With more than 13 sets of patents filed to date in the U.S. and internationally around various properties of CBLB502 and related compounds, we believe we have protected the potentially broad uses of our Protectan technology. The receipt of our first U.S. patent for protection from radiation is a major milestone in our development of CBLB502 and we continue to advance our work in this and other areas of protection from acute stresses."

About CBLB502

CBLB502 is a derivative of a microbial protein, which has demonstrated the capacity to reduce injury from acute stresses, such as radiation in animal models. CBLB502 mobilizes several cell protective mechanisms, including inhibition of programmed cell death (apoptosis), reduction of oxidative damage and induction of regeneration-promoting cytokines.

CBLB502 is being developed under the U.S. Food and Drug Administration's Animal Efficacy Rule to treat Acute Radiation Syndrome (ARS) or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon/ dirty bomb, or from a nuclear accident. This approval pathway requires demonstration of efficacy in representative animal models and safety and drug metabolism testing in healthy human volunteers.

Evidence of CBLB502's mechanism of action and activity in animal models was published in Science Magazine in April 2008 (Science, 2008, vol. 320, pp. 226-230). Data from 50 subjects in an initial Phase I safety and tolerability study indicated that CBLB502 was well tolerated and that normalized biomarker results corresponded to previously demonstrated activity in animal models of ARS. There is currently no FDA approved medical countermeasure to treat ARS.

CBLB502 is also being developed as a supportive care measure to reduce and prevent occurrence of side effects of radiotherapy or chemotherapy in cancer treatment.

Source
Cleveland BioLabs, Inc.

• Additional
• References
• Citations